A structured debate: Immediate versus deferred androgen suppression in prostate cancer - Evidence for deferred treatment

Journal of Urology

Volumn 166, Issue 2, 2001, Pages 508-516

  Walsh, Patrick C ^a   DeWeese, Theodore L ^a   Eisenberger, Mario A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Androgens; Prostate; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; HORMONE;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DEPRESSION; DRUG INDUCED DISEASE; FATIGUE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; LYMPH NODE METASTASIS; MALE; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEXUAL DYSFUNCTION; WEIGHT GAIN;

EID: 0034932358     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65972-1     Document Type: Article

References (45)

1. Survival following castration for prostatic cancer
2. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases
3. The influence of hormonal therapy on survival of men with advanced prostatic cancer
4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
5. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate specific antigen gene in the LNCaP prostate tumor model
6. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
7. Prognosis and prostatic volume changes during endocrine management of prostate cancer: A longitudinal study
8. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327-H adenocarcinoma
9. Androgen-independent prostate cancer progression in the TRAMP model
10. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
11. Growth-stimulatory effect of androgen-induced autocrine growth factor(s) secreted from Shionogi carcinoma 115 cells on androgen-unresponsive cancer cells in a paracrine mechanism
12. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
13. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy
14. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer
15. Orchiectomy for advanced prostatic carcinoma. A reevaluation
16. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
17. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
18. Editorial comment
19. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council
20. Endocrine treatment of prostate cancer: Recent developments and the future. Part I: Maximal androgen blockage, early vs. delayed endocrine treatment and side-effects
21. Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation?
22. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
23. (T1-3, N1-3, M0) prostate cancer: A case-controlled comparison of conservative treatment versus radical prostatectomy
24. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation
25. Early androgen deprivation for prostate cancer?
26. Prognosis of patients with stage D1 prostate cancer following radical prostatectomy with and without early endocrine therapy
27. Prognostic factors in men with stage D1 prostate cancer: Identification of patients less likely to have prolonged survival after radical prostatectomy
28. Cancer volume of lymph node metastasis predicts progression in prostate cancer
29. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrent after radical prostatectomy
30. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation
31. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
32. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement. A prospective randomized study
33. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85
34. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate
35. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long-term results of a prospective randomized study
36. Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate
37. Quality of life issues relating to endocrine treatment options
38. A randomized comparison of Casodex™ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
39. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years
40. Comparison of "Casodex" (bicalutamide) 150 mg monotherapy with castration in previously untreated nonmetastatic prostate cancer: Mature survival results
41. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate-specific antigen
42. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma
43. Natural history of progression after PSA elevation following radical prostatectomy
44. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer